{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:17:35Z","timestamp":1792887455663,"version":"4.5.0"},"reference-count":94,"publisher":"American Medical Association (AMA)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,5,11]]},"DOI":"10.1001\/jama.2021.1640","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T12:28:30Z","timestamp":1620736110000},"page":"1874","source":"Crossref","is-referenced-by-count":214,"title":["Diagnosis and Management of Headache"],"prefix":"10.1001","volume":"325","author":[{"given":"Matthew S.","family":"Robbins","sequence":"first","affiliation":[{"name":"Department of Neurology, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"jrv210004r1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/0895-4356(91)90147-2","article-title":"Epidemiology of headache in a general population: a prevalence study.","volume":"44","author":"Rasmussen","year":"1991","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"jrv210004r2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/head.2015.55.issue-1","article-title":"The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies.","volume":"55","author":"Burch","year":"2015","journal-title":"Headache"},{"issue":"1","key":"jrv210004r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"issue":"2","key":"jrv210004r4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1055\/s-0030-1249220","article-title":"The epidemiology of primary headache disorders.","volume":"30","author":"Robbins","year":"2010","journal-title":"Semin Neurol"},{"issue":"2","key":"jrv210004r5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing.","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol Rev"},{"issue":"10","key":"jrv210004r6","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1111\/head.12468","article-title":"Trigger factors and premonitory features of migraine attacks: summary of studies.","volume":"54","author":"Pavlovic","year":"2014","journal-title":"Headache"},{"issue":"3","key":"jrv210004r7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1212\/WNL.0000000000002789","article-title":"The migraine postdrome: an electronic diary study.","volume":"87","author":"Giffin","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"jrv210004r8","first-page":"87","article-title":"Diagnosing headache: clinical clues and clinical rules.","volume":"3","author":"Dodick","year":"2003","journal-title":"Adv Stud Med"},{"issue":"3","key":"jrv210004r9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1212\/WNL.0000000000006697","article-title":"Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list.","volume":"92","author":"Do","year":"2019","journal-title":"Neurology"},{"issue":"5","key":"jrv210004r10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2165\/11315980-000000000-00000","article-title":"Management of headache in the elderly.","volume":"27","author":"Robbins","year":"2010","journal-title":"Drugs Aging"},{"issue":"12","key":"jrv210004r11","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1212\/WNL.0000000000001954","article-title":"Acute headache diagnosis in pregnant women: a hospital-based study.","volume":"85","author":"Robbins","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"jrv210004r12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/head.2018.58.issue-6","article-title":"A hospital based retrospective study of acute postpartum headache.","volume":"58","author":"Vgontzas","year":"2018","journal-title":"Headache"},{"issue":"4","key":"jrv210004r13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1468-2982.2009.01970.x","article-title":"Headache attributed to intracranial tumours: a prospective cohort study.","volume":"30","author":"Valentinis","year":"2010","journal-title":"Cephalalgia"},{"issue":"8","key":"jrv210004r14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/head.2014.54.issue-8","article-title":"Giant cell arteritis.","volume":"54","author":"Smith","year":"2014","journal-title":"Headache"},{"issue":"11S","key":"jrv210004r15","doi-asserted-by":"publisher","first-page":"S364","DOI":"10.1016\/j.jacr.2019.05.030","article-title":"ACR appropriateness criteria headache.","volume":"16","author":"Whitehead","year":"2019","journal-title":"J Am Coll Radiol"},{"issue":"2","key":"jrv210004r16","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/head.v60.2","article-title":"Neuroimaging for migraine: the American Headache Society systematic review and evidence-based guideline.","volume":"60","author":"Evans","year":"2020","journal-title":"Headache"},{"issue":"1","key":"jrv210004r17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archneur.64.1.25","article-title":"Trigeminal autonomic cephalgias due to structural lesions: a review of 31 cases.","volume":"64","author":"Favier","year":"2007","journal-title":"Arch Neurol"},{"issue":"5","key":"jrv210004r18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy.","volume":"68","author":"Lipton","year":"2007","journal-title":"Neurology"},{"issue":"8","key":"jrv210004r19","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/hed.2008.48.issue-8","article-title":"Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study.","volume":"48","author":"Bigal","year":"2008","journal-title":"Headache"},{"issue":"4","key":"jrv210004r20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","article-title":"Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers.","volume":"81","author":"Buse","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"jrv210004r21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/head.2019.59.issue-3","article-title":"Migraine progression: a systematic review.","volume":"59","author":"Buse","year":"2019","journal-title":"Headache"},{"issue":"8","key":"jrv210004r22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1212\/WNL.0b013e31820d8af2","article-title":"Rates, predictors, and consequences of remission from chronic migraine to episodic migraine.","volume":"76","author":"Manack","year":"2011","journal-title":"Neurology"},{"issue":"1-2","key":"jrv210004r23","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/jnr.23903","article-title":"Sex-related influences in migraine.","volume":"95","author":"Pavlovic","year":"2017","journal-title":"J Neurosci Res"},{"issue":"1","key":"jrv210004r24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s10194-017-0815-1","article-title":"Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC).","volume":"18","author":"Sacco","year":"2017","journal-title":"J Headache Pain"},{"issue":"8","key":"jrv210004r25","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1212\/WNL.0b013e3181d0cc8b","article-title":"Migraine and cardiovascular disease: a population-based study.","volume":"74","author":"Bigal","year":"2010","journal-title":"Neurology"},{"issue":"22","key":"jrv210004r26","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1001\/jama.2020.7172","article-title":"Association of migraine with aura and other risk factors with incident cardiovascular disease in women.","volume":"323","author":"Kurth","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"jrv210004r27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/head.2015.55.issue-1","article-title":"The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies.","volume":"55","author":"Marmura","year":"2015","journal-title":"Headache"},{"issue":"9294","key":"jrv210004r28","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","article-title":"Oral triptans (serotonin 5-HT(1B\/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.","volume":"358","author":"Ferrari","year":"2001","journal-title":"Lancet"},{"issue":"10200","key":"jrv210004r29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.","volume":"394","author":"Croop","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"jrv210004r30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine.","volume":"381","author":"Lipton","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv210004r31","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"issue":"24","key":"jrv210004r32","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study.","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"key":"jrv210004r33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/head.2019.59.issue-S2","article-title":"Neuromodulation for the acute and preventive therapy of migraine and cluster headache.","volume":"59","author":"Halker Singh","year":"2019","journal-title":"Headache"},{"issue":"6","key":"jrv210004r34","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.55.6.754","article-title":"Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.","volume":"55","author":"Silberstein","year":"2000","journal-title":"Neurology"},{"issue":"19","key":"jrv210004r35","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1212\/WNL.0000000000010634","article-title":"Quality improvement in neurology: Headache Quality Measurement Set.","volume":"95","author":"Robbins","year":"2020","journal-title":"Neurology"},{"issue":"7","key":"jrv210004r36","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/0333102413515348","article-title":"A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study.","volume":"34","author":"Stovner","year":"2014","journal-title":"Cephalalgia"},{"issue":"6","key":"jrv210004r37","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/hed.2010.50.issue-6","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"issue":"3","key":"jrv210004r38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1).","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"issue":"13","key":"jrv210004r39","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"issue":"6","key":"jrv210004r40","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a phase 3 randomized trial of erenumab for episodic migraine.","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"issue":"22","key":"jrv210004r41","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine.","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv210004r42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"issue":"19","key":"jrv210004r43","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial.","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"issue":"22","key":"jrv210004r44","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine.","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"jrv210004r45","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN Study.","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"issue":"8","key":"jrv210004r46","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial.","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"issue":"9","key":"jrv210004r47","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 Randomized Clinical Trial.","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"issue":"10","key":"jrv210004r48","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/jnnp-2016-313458","article-title":"Randomised clinical trial comparing melatonin 3?mg, amitriptyline 25?mg and placebo for migraine prevention.","volume":"87","author":"Gon\u00e7alves","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"jrv210004r49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","article-title":"The American Headache Society position statement on integrating new migraine treatments into clinical practice.","volume":"59","author":"American Headache Society","year":"2019","journal-title":"Headache"},{"issue":"2","key":"jrv210004r50","first-page":"S1","article-title":"Canadian Headache Society guideline for migraine prophylaxis.","volume":"39","author":"Pringsheim","year":"2012","journal-title":"Can J Neurol Sci"},{"issue":"17","key":"jrv210004r51","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology"},{"issue":"17","key":"jrv210004r52","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1212\/WNL.0b013e3182535d0c","article-title":"Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.","volume":"78","author":"Holland","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"jrv210004r53","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2147\/nedt.2006.2.issue-3","article-title":"Prophylaxis of migraine.","volume":"2","author":"Garza","year":"2006","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"jrv210004r55","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/head.v60.2","article-title":"Most bothersome symptom in persons with migraine: results from the Migraine in America Symptoms and Treatment (MAST) Study.","volume":"60","author":"Munjal","year":"2020","journal-title":"Headache"},{"issue":"10","key":"jrv210004r56","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/head.2016.56.issue-10","article-title":"Predicting inadequate response to acute migraine medication: results From the American Migraine Prevalence and Prevention (AMPP) Study.","volume":"56","author":"Lipton","year":"2016","journal-title":"Headache"},{"issue":"1","key":"jrv210004r57","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1056\/NEJMct0910887","article-title":"Triptan therapy in migraine.","volume":"363","author":"Loder","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv210004r58","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/hed.2004.44.issue-5","article-title":"Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.","volume":"44","author":"Dodick","year":"2004","journal-title":"Headache"},{"issue":"1","key":"jrv210004r59","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","article-title":"Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.","volume":"20","author":"Shapiro","year":"2019","journal-title":"J Headache Pain"},{"issue":"1","key":"jrv210004r60","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/head.v60.1","article-title":"Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial.","volume":"60","author":"Ailani","year":"2020","journal-title":"Headache"},{"issue":"23","key":"jrv210004r61","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine.","volume":"381","author":"Dodick","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"jrv210004r62","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II Randomized Clinical Trial.","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"jrv210004r63","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jamaneurol.2017.5144","article-title":"Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome.","volume":"75","author":"Orlova","year":"2018","journal-title":"JAMA Neurol"},{"issue":"6","key":"jrv210004r64","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/hed.2010.50.issue-6","article-title":"The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper.","volume":"50","author":"Evans","year":"2010","journal-title":"Headache"},{"issue":"8","key":"jrv210004r65","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1177\/0333102420911461","article-title":"Unrecognized challenges of treating status migrainosus: an observational study.","volume":"40","author":"Iljazi","year":"2020","journal-title":"Cephalalgia"},{"issue":"9","key":"jrv210004r66","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S1474-4422(19)30146-2","article-title":"Pathophysiology, prevention, and treatment of medication overuse headache.","volume":"18","author":"Diener","year":"2019","journal-title":"Lancet Neurol"},{"issue":"20","key":"jrv210004r67","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial.","volume":"92","author":"Tepper","year":"2019","journal-title":"Neurology"},{"issue":"10161","key":"jrv210004r68","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"jrv210004r69","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/0333102418788347","article-title":"Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study.","volume":"38","author":"Ashina","year":"2018","journal-title":"Cephalalgia"},{"issue":"10203","key":"jrv210004r70","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"jrv210004r71","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1111\/head.v59.10","article-title":"FORWARD Study: evaluating the comparative effectiveness of onabotulinumtoxina and topiramate for headache prevention in adults with chronic migraine.","volume":"59","author":"Rothrock","year":"2019","journal-title":"Headache"},{"issue":"2","key":"jrv210004r72","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/head.v60.2","article-title":"Workforce gap analysis in the field of headache medicine in the United States.","volume":"60","author":"Begasse de Dhaem","year":"2020","journal-title":"Headache"},{"issue":"5","key":"jrv210004r73","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/head.v60.5","article-title":"Migraine care in the era of COVID-19: clinical pearls and plea to insurers.","volume":"60","author":"Szperka","year":"2020","journal-title":"Headache"},{"key":"jrv210004r74","doi-asserted-by":"publisher","first-page":"c4871","DOI":"10.1136\/bmj.c4871","article-title":"Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial.","volume":"341","author":"Holroyd","year":"2010","journal-title":"BMJ"},{"issue":"9","key":"jrv210004r75","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1111\/head.v59.9","article-title":"Does mindfulness-based cognitive therapy for migraine reduce migraine-related disability in people with episodic and chronic migraine? a phase 2b pilot randomized clinical trial.","volume":"59","author":"Seng","year":"2019","journal-title":"Headache"},{"key":"jrv210004r76","article-title":"Effectiveness of mindfulness meditation vs headache education for adults with migraine: a randomized clinical trial.","author":"Wells","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"6","key":"jrv210004r77","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/head.v60.6","article-title":"Behavioral therapy preferences in people with migraine.","volume":"60","author":"Minen","year":"2020","journal-title":"Headache"},{"issue":"7","key":"jrv210004r78","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/head.12375","article-title":"Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry.","volume":"54","author":"Ephross","year":"2014","journal-title":"Headache"},{"issue":"5","key":"jrv210004r79","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1001\/jama.279.5.381","article-title":"Epidemiology of tension-type headache.","volume":"279","author":"Schwartz","year":"1998","journal-title":"JAMA"},{"issue":"6","key":"jrv210004r80","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11916-010-0146-2","article-title":"Epidemiology of tension-type headache.","volume":"14","author":"Crystal","year":"2010","journal-title":"Curr Pain Headache Rep"},{"issue":"10","key":"jrv210004r81","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1046\/j.1526-4610.2000.00143.x","article-title":"2000 Wolfe Award: sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study.","volume":"40","author":"Lipton","year":"2000","journal-title":"Headache"},{"issue":"11","key":"jrv210004r82","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1468-1331.2010.03070.x","article-title":"EFNS guideline on the treatment of tension-type headache: report of an EFNS task force.","volume":"17","author":"Bendtsen","year":"2010","journal-title":"Eur J Neurol"},{"key":"jrv210004r83","article-title":"Acupuncture for the prevention of tension-type headache.","volume":"4","author":"Linde","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"jrv210004r84","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1111\/head.2014.54.issue-9","article-title":"Trigger point injections for headache disorders: expert consensus methodology and narrative review.","volume":"54","author":"Robbins","year":"2014","journal-title":"Headache"},{"issue":"6","key":"jrv210004r85","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1468-2982.2008.01592.x","article-title":"The incidence and prevalence of cluster headache: a meta-analysis of population-based studies.","volume":"28","author":"Fischera","year":"2008","journal-title":"Cephalalgia"},{"issue":"7","key":"jrv210004r86","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/head.2016.56.issue-7","article-title":"Treatment of cluster headache: the American Headache Society evidence-based guidelines.","volume":"56","author":"Robbins","year":"2016","journal-title":"Headache"},{"issue":"2","key":"jrv210004r87","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa1813440","article-title":"Trial of galcanezumab in prevention of episodic cluster headache.","volume":"381","author":"Goadsby","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"jrv210004r88","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1212\/WNL.0b013e3181dad5de","article-title":"Clinical and prognostic subforms of new daily-persistent headache.","volume":"74","author":"Robbins","year":"2010","journal-title":"Neurology"},{"issue":"13","key":"jrv210004r89","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/WNL.0b013e3182a55f17","article-title":"Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children.","volume":"81","author":"Friedman","year":"2013","journal-title":"Neurology"},{"issue":"10","key":"jrv210004r90","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/ene.2018.25.issue-10","article-title":"Meta-analysis and systematic review of population-based epidemiological studies in idiopathic intracranial hypertension.","volume":"25","author":"McCluskey","year":"2018","journal-title":"Eur J Neurol"},{"issue":"16","key":"jrv210004r91","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1001\/jama.2014.3312","article-title":"Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.","volume":"311","author":"Wall","year":"2014","journal-title":"JAMA"},{"issue":"8","key":"jrv210004r92","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1111\/head.2017.57.issue-8","article-title":"Headache in idiopathic intracranial hypertension: findings from the Idiopathic Intracranial Hypertension Treatment Trial.","volume":"57","author":"Friedman","year":"2017","journal-title":"Headache"},{"issue":"6","key":"jrv210004r93","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10194-007-0421-8","article-title":"Frequency of spontaneous intracranial hypotension in the emergency department.","volume":"8","author":"Schievink","year":"2007","journal-title":"J Headache Pain"},{"issue":"4","key":"jrv210004r94","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.nic.2019.07.006","article-title":"Spontaneous intracranial hypotension: pathogenesis, diagnosis, and treatment.","volume":"29","author":"Kranz","year":"2019","journal-title":"Neuroimaging Clin N Am"},{"key":"jrv210004r54","first-page":"125","volume-title":"Neurology In Practice: Headache","author":"Young","year":"2013"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2779823\/jama_robbins_2021_rv_210004_1620430618.04019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T11:54:15Z","timestamp":1699012455000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2779823"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":94,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,5,11]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.1640","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,11]]}}}